Antiviral drugs are the main, if only, method of treatment of major viral disease conditions. This Theta Report is the first in a three-volume
series of market research reports on global anti-infective drug markets.
In order to recognize the opportunities presented by the antiviral pharmaceuticals market, companies need to be aware of treatment advances, as
well as probable future offerings and their projected impact on future drug sales. This report presents global market analysis by geographic region
and by major drug products, as well as competitive positions of major players and competitive dynamics affecting market change.
Major viral disease conditions for which antivirals are used as in this report are:
- Hepatitis B
- Hepatitis C
- Human immunodeficiency virus (HIV)
- Herpes virus
- Influenza
- Respiratory syncytial virus (RSV)
- Human papillomavirus (HPV)
Classes of antiviral drugs discussed include:
- Interferons
- Nucleoside reverse transcriptase inhibitors (NRTIs)
- Non-nucleoside reverse transcriptase inhibitors (nNRTIs)
- Protease inhibitors
- Other drugs: anti-influenza agents, neuraminidase inhibitors, immunoglobulins, immunomodulators
An essential strategic resource, Theta' s Antivirals: Global Anti-Infectives
Markets Vol. I answers the following questions:
- What conditions currently require treatment with antivirals?
- What are the healthcare costs of these conditions?
- Why are these conditions such a problem?
- What antiviral products are currently available to treat these conditions?
- What antiviral products are currently in development for these conditions?
- What are the current market sizes and forecasted market projections for antiviral drugs for each condition, based on drug class/product and
geographic region?
- Who are the major competitors and what are their current market shares?
View Cart
